BYAKANGELICIN

TargetMol
Product Code: TAR-T5813
Supplier: TargetMol
CodeSizePrice
TAR-T5813-1mg1mg£106.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5813-5mg5mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5813-1mL1 mL * 10 mM (in DMSO)£163.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5813-10mg10mg£203.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5813-25mg25mg£309.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5813-50mg50mg£455.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5813-100mg100mg£623.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
BYAKANGELICIN,a main furanocoumarin constituent isolated and characterized as an aldose reductase inhibitor,and is effective for the treatment of sugar cataracts and diabetic neuropathy and hence might be useful as a lead compound for the development of new type drugs for clinical use.
CAS:
482-25-7
Formula:
C17H18O7
Molecular Weight:
334.32
Pathway:
Metabolism; Endocrinology/Hormones
Purity:
0.9986
SMILES:
COc1c2ccoc2c(OC[C@@H](O)C(C)(C)O)c2oc(=O)ccc12
Target:
Reductase

References

Shin K H , Lim S S , Kim D K . Effect of byakangelicin, an aldose reductase inhibitor, on galactosemic cataracts, the polyol contents and Na(+), K(+)ATPase activity in sciatic nerves of strepto-zotocin-induced diabetic rats.[J]. Phytomedicine International Journal of Phytotherapy & Phytopharmacology, 1998, 5(2):121. Yang J , Luan X , Gui H , et al. Byakangelicin induces cytochrome P450 3A4 expression via transactivation of pregnane X receptors in human hepatocytes[J]. British Journal of Pharmacology, 2010, 162(2):441-451.